Canadian Study
Persistent immune activation in chronic HIV infection
B-cell subset alterations and correlated factors in HIV-1 infection
Development of sulphated and naphthylsulphonated carbosilane dendrimers as topical microbicides to prevent HIV-1 sexual transmission
HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy
Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups
Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV
Field effectiveness of combination antiretroviral prophylaxis for the prevention of mother-to-child HIV transmission in rural Zambia
Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men
Incident tuberculosis and risk factors among HIV-infected children in Tanzania
Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients
Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate ≥60 ml/min per 1.73 m2
The effect of HIV infection on longitudinal lung function decline among IDUs
Spatiotemporal dynamics of the HIV-1 CRF06_cpx epidemic in western Africa
Higher rates of AIDS during the first year of antiretroviral therapy among migrants
Intimate partner violence is associated with incident HIV infection in women in Uganda
Serum albumin and short-term risk for mortality and cardiovascular disease among HIV-infected veterans
HIV infection and lung function decline
Mesenchymal stem cell therapy in HIV-infected HAART-treated nonimmune responders restores immune competence
Adipokines and vascular health in treated HIV infection
Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy
An unusual case of HIV virologic failure during treatment with boosted atazanavir
Is the current use of ‘positivity’ thresholds meaningful for evaluating HIV-vaccine immunogenicity endpoints?